C
César Sánchez
High Impact
Associate profesor
faculty
COM | Internal Med Hem-Onc
20 h-index
143 pubs
2,481 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
César Sánchez is an Associate Professor in the Department of Internal Medicine, Hematology-Oncology at the University of Arkansas for Medical Sciences. His research interests encompass various aspects of cancer, with a particular focus on breast cancer and gastrointestinal cancers. He has investigated the prognostic impact of breast cancer detection methods in Chilean cohorts, the association between obesity and early recurrence in breast cancer patients responding to neoadjuvant chemotherapy, and the quality of life implications of upper-limb disability and lymphedema severity in breast cancer patients.
His work also extends to clinical trials and treatment strategies for advanced cancers. He has contributed to studies evaluating novel therapeutic agents, including pembrolizumab for gastric cancer and ripretinib for gastrointestinal stromal tumors, with a focus on biomarker analysis such as circulating tumor DNA (ctDNA). Sánchez is also involved in research exploring multi-stage processes for chemotherapy scheduling and capacity determination, and the co-design of mobile applications to engage breast cancer patients in reporting their health experiences. His scholarly output includes 148 publications and he has an h-index of 20 with over 2,400 citations, designating him as a highly cited researcher.
Metrics
- h-index: 20
- Publications: 143
- Citations: 2,481
Selected Publications
-
26-A-9693-ACC PREDICTION OF 1-YEAR MAJOR ADVERSE CARDIAC EVENTS IN CAR-T RECIPIENTS USING RISK SCORE MODELING: EXPANDED WHOLE-COHORT ANALYSIS (2026)
-
Long term outcomes of older patients with classical hodgkin lymphoma: an analysis of the Texas cancer registry (2025)
-
Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025)
-
Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis (2025)
-
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)
-
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)
-
Pricing, availability, and affordability of cancer medicines in 5 middle-income countries in South America. (2025)
-
PREDICTORS OF ADVERSE CARDIOVASCULAR EVENTS AFTER CHIMERIC ANTIGEN T-CELL (CAR-T) THERAPY (2025)
-
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)
-
Impact of Response to Bridging Therapy on Outcomes of CAR-T Therapy in Relapsed/Refractory DLBCL: A Single Center Retrospective Analysis (2024)
-
Gut Microbiome Diversity and Composition Changes Post Allogeneic Hematopoietic Stem Cell Transplant (AlloSCT): A Single-Center Prospective Analysis (2024)
-
Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry (2024)
-
Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy (2024)
-
Cutaneous Involvement By Peripheral T-Cell Lymphoma: Incidence, Characteristics, Treatment Trends, and Outcomes in the United States (2000-2021) (2024)
-
Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case (2024)
Grants & Funding
- S2114: A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma SouthWest Oncology Group Principal Investigator
- 276212 Open-label, Multicenter Phase 2 Study Evaluating the Efficacy&Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor T-cell Therapy in Patients w/ Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy CARGO Therapeutics, Inc. Principal Investigator
- 276212 Open-label, Multicenter Phase 2 Study Evaluating the Efficacy&Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor T-cell Therapy in Patients w/ Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy CARGO Therapeutics, Inc. Principal Investigator
Collaboration Network
Top Collaborators
Francisco Acevedo
Pontificia Universidad Católica de Chile (CL)
26 shared publications
- Upper-Limb Disability and the Severity of Lymphedema Reduce the Quality of Life of Patients with Breast Cancer-Related Lymphedema
- Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients
- Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
- Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
- Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
Showing 5 of 26 shared publications
Benjamín Walbaum
Hospital Clínic de Barcelona (ES)
22 shared publications
- Upper-Limb Disability and the Severity of Lymphedema Reduce the Quality of Life of Patients with Breast Cancer-Related Lymphedema
- Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients
- Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
- Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
- Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
Showing 5 of 22 shared publications
Tomás Merino
Pontificia Universidad Católica de Chile (CL)
19 shared publications
- Upper-Limb Disability and the Severity of Lymphedema Reduce the Quality of Life of Patients with Breast Cancer-Related Lymphedema
- Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients
- Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
- Barriers for research activities in residency programs: A mix-methods study
- Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
Showing 5 of 19 shared publications
Mauricio P. Pinto
Fundación Arturo López Pérez (CL)
12 shared publications
- Upper-Limb Disability and the Severity of Lymphedema Reduce the Quality of Life of Patients with Breast Cancer-Related Lymphedema
- Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients
- Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
- Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
- Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data
Showing 5 of 12 shared publications
Lidia Medina
Pontificia Universidad Católica de Chile (CL)
10 shared publications
- Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients
- Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
- Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
- Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data
- Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
Showing 5 of 10 shared publications
Sabrina Muñiz
Pontificia Universidad Católica de Chile (CL)
8 shared publications
- Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
- Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
- Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data
- Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital
- Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
Showing 5 of 8 shared publications
Mauricio Camus
Pontificia Universidad Católica de Chile (CL)
8 shared publications
- Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients
- Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
- Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
- Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data
- Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
Showing 5 of 8 shared publications
Carolina Ibáñez
Pontificia Universidad Católica de Chile (CL)
6 shared publications
- Upper-Limb Disability and the Severity of Lymphedema Reduce the Quality of Life of Patients with Breast Cancer-Related Lymphedema
- Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
- High linoleic acid levels in red blood cells predict a poor response to neoadjuvant chemotherapy in human epidermal growth factor receptor type 2-positive breast cancer patients
- Impact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy Incidence in Patients With Gastric Cancer: A Prospective Cohort Study
- Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry
Showing 5 of 6 shared publications
Constanza Guerra
Complejo Asistencial Sótero del Río (CL)
6 shared publications
- Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
- Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
- Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital
- Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
- Abstract P3-03-19: Real-world data of clinical characteristics, risk factors and outcomes of Chilean triple-negative breast cancer patients
Showing 5 of 6 shared publications
Marisel Navarro
Complejo Asistencial Sótero del Río (CL)
6 shared publications
- Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
- Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
- Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital
- Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
- Abstract P3-03-19: Real-world data of clinical characteristics, risk factors and outcomes of Chilean triple-negative breast cancer patients
Showing 5 of 6 shared publications
Manuel Manzor
Complejo Asistencial Sótero del Río (CL)
6 shared publications
- Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
- Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
- Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital
- Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
- Abstract P3-03-19: Real-world data of clinical characteristics, risk factors and outcomes of Chilean triple-negative breast cancer patients
Showing 5 of 6 shared publications
Raúl Martínez‐Fernández
Complejo Asistencial Sótero del Río (CL)
6 shared publications
- Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
- Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
- Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital
- Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
- Abstract P3-03-19: Real-world data of clinical characteristics, risk factors and outcomes of Chilean triple-negative breast cancer patients
Showing 5 of 6 shared publications
X. Cynthia
6 shared publications
- Supplementary Table 1 and Figure legend for Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Supplementary Table 1 and Figure legend for Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Data from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Showing 5 of 6 shared publications
Feng Gao
6 shared publications
- Supplementary Table 1 and Figure legend for Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Supplementary Table 1 and Figure legend for Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Data from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Showing 5 of 6 shared publications
Robert G. Crowder
6 shared publications
- Supplementary Table 1 and Figure legend for Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Supplementary Table 1 and Figure legend for Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
- Data from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics
Ralph Broadwater
University of Arkansas for Medical Sciences
Breast Cancer Treatment Studies
Cancer Treatment and Pharmacology
Health disparities and outcomes
Caleb A Shelton
Harding University Main Campus
Breast Cancer Treatment Studies
Cancer Treatment and Pharmacology
Health disparities and outcomes
Landry K. Kamdem
Harding University Main Campus
Breast Cancer Treatment Studies
Cancer Treatment and Pharmacology
Health disparities and outcomes
Vutha Nhim
University of Arkansas for Medical Sciences
Breast Cancer Treatment Studies
Cancer Treatment and Pharmacology
Health disparities and outcomes
Laura F. Hutchins
University of Arkansas for Medical Sciences
Breast Cancer Treatment Studies
Cancer Treatment and Pharmacology
Health disparities and outcomes
Sindhu Janarthanam Malapati
University of Arkansas for Medical Sciences
Breast Cancer Treatment Studies
Cancer Treatment and Pharmacology
Health disparities and outcomes